Clinical Trial Update: Camsirubicin + Pegfilgrastim to Determine MTD in ASTS [Phase 1]

View source ↗

Summary

Phase 1 trial of Camsirubicin plus Pegfilgrastim to determine the maximum tolerated dose in advanced soft-tissue sarcoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Camsirubicin (camsirubicin)
• Pegfilgrastim (pegfilgrastim)

Snippet

Sponsor: Monopar Therapeutics | Conditions: Advanced Soft-tissue Sarcoma | Phase 1 | Status: TERMINATED